vs
EXACT SCIENCES CORP（EXAS）与Guardant Health, Inc.（GH）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Guardant Health, Inc.的3.1倍（$878.4M vs $281.3M）。EXACT SCIENCES CORP净利率更高（-9.8% vs -45.7%，领先35.9%）。Guardant Health, Inc.同比增速更快（39.4% vs 23.1%）。EXACT SCIENCES CORP自由现金流更多（$120.4M vs $-54.2M）。过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
EXAS vs GH — 直观对比
营收规模更大
EXAS
是对方的3.1倍
$281.3M
营收增速更快
GH
高出16.2%
23.1%
净利率更高
EXAS
高出35.9%
-45.7%
自由现金流更多
EXAS
多$174.7M
$-54.2M
两年增速更快
GH
近两年复合增速
17.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $281.3M |
| 净利润 | $-86.0M | $-128.5M |
| 毛利率 | 70.1% | 64.6% |
| 营业利润率 | -9.4% | -43.0% |
| 净利率 | -9.8% | -45.7% |
| 营收同比 | 23.1% | 39.4% |
| 净利润同比 | 90.1% | -15.8% |
| 每股收益（稀释后） | $-0.45 | $-1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASGH
| Q4 25 | $878.4M | $281.3M | ||
| Q3 25 | $850.7M | $265.2M | ||
| Q2 25 | $811.1M | $232.1M | ||
| Q1 25 | $706.8M | $203.5M | ||
| Q4 24 | $713.4M | $201.8M | ||
| Q3 24 | $708.7M | $191.5M | ||
| Q2 24 | $699.3M | $177.2M | ||
| Q1 24 | $637.5M | $168.5M |
净利润EXASGH
| Q4 25 | $-86.0M | $-128.5M | ||
| Q3 25 | $-19.6M | $-92.7M | ||
| Q2 25 | $-1.2M | $-99.9M | ||
| Q1 25 | $-101.2M | $-95.2M | ||
| Q4 24 | $-864.6M | $-111.0M | ||
| Q3 24 | $-38.2M | $-107.8M | ||
| Q2 24 | $-15.8M | $-102.6M | ||
| Q1 24 | $-110.2M | $-115.0M |
毛利率EXASGH
| Q4 25 | 70.1% | 64.6% | ||
| Q3 25 | 68.6% | 64.7% | ||
| Q2 25 | 69.3% | 65.0% | ||
| Q1 25 | 70.8% | 63.3% | ||
| Q4 24 | 69.0% | 61.6% | ||
| Q3 24 | 69.4% | 61.1% | ||
| Q2 24 | 69.8% | 59.1% | ||
| Q1 24 | 70.0% | 61.2% |
营业利润率EXASGH
| Q4 25 | -9.4% | -43.0% | ||
| Q3 25 | -3.0% | -37.3% | ||
| Q2 25 | -0.3% | -45.9% | ||
| Q1 25 | -13.6% | -54.6% | ||
| Q4 24 | -122.8% | -62.4% | ||
| Q3 24 | -5.6% | -61.3% | ||
| Q2 24 | -3.8% | -56.8% | ||
| Q1 24 | -16.7% | -59.2% |
净利率EXASGH
| Q4 25 | -9.8% | -45.7% | ||
| Q3 25 | -2.3% | -35.0% | ||
| Q2 25 | -0.1% | -43.0% | ||
| Q1 25 | -14.3% | -46.8% | ||
| Q4 24 | -121.2% | -55.0% | ||
| Q3 24 | -5.4% | -56.3% | ||
| Q2 24 | -2.3% | -57.9% | ||
| Q1 24 | -17.3% | -68.2% |
每股收益（稀释后）EXASGH
| Q4 25 | $-0.45 | $-1.01 | ||
| Q3 25 | $-0.10 | $-0.74 | ||
| Q2 25 | $-0.01 | $-0.80 | ||
| Q1 25 | $-0.54 | $-0.77 | ||
| Q4 24 | $-4.69 | $-0.90 | ||
| Q3 24 | $-0.21 | $-0.88 | ||
| Q2 24 | $-0.09 | $-0.84 | ||
| Q1 24 | $-0.60 | $-0.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $378.2M |
| 总债务越低越好 | — | $1.5B |
| 股东权益账面价值 | $2.4B | $-99.3M |
| 总资产 | $5.9B | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASGH
| Q4 25 | $964.7M | $378.2M | ||
| Q3 25 | $1.0B | $580.0M | ||
| Q2 25 | $858.4M | $629.1M | ||
| Q1 25 | $786.2M | $698.6M | ||
| Q4 24 | $1.0B | $525.5M | ||
| Q3 24 | $1.0B | $585.0M | ||
| Q2 24 | $946.8M | $933.7M | ||
| Q1 24 | $652.1M | $1.0B |
总债务EXASGH
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EXASGH
| Q4 25 | $2.4B | $-99.3M | ||
| Q3 25 | $2.5B | $-354.5M | ||
| Q2 25 | $2.5B | $-305.5M | ||
| Q1 25 | $2.4B | $-250.8M | ||
| Q4 24 | $2.4B | $-139.6M | ||
| Q3 24 | $3.2B | $-60.1M | ||
| Q2 24 | $3.2B | $-1.6M | ||
| Q1 24 | $3.1B | $68.3M |
总资产EXASGH
| Q4 25 | $5.9B | $2.0B | ||
| Q3 25 | $5.9B | $1.3B | ||
| Q2 25 | $5.8B | $1.3B | ||
| Q1 25 | $5.7B | $1.3B | ||
| Q4 24 | $5.9B | $1.5B | ||
| Q3 24 | $6.7B | $1.5B | ||
| Q2 24 | $6.7B | $1.6B | ||
| Q1 24 | $6.4B | $1.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $-26.4M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $-54.2M |
| 自由现金流率自由现金流/营收 | 13.7% | -19.3% |
| 资本支出强度资本支出/营收 | 3.6% | 9.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | $-233.1M |
8季度趋势，按日历期对齐
经营现金流EXASGH
| Q4 25 | $151.7M | $-26.4M | ||
| Q3 25 | $219.9M | $-35.4M | ||
| Q2 25 | $89.0M | $-60.3M | ||
| Q1 25 | $30.8M | $-62.7M | ||
| Q4 24 | $47.1M | $-64.5M | ||
| Q3 24 | $138.7M | $-51.1M | ||
| Q2 24 | $107.1M | $-94.0M | ||
| Q1 24 | $-82.3M | $-30.3M |
自由现金流EXASGH
| Q4 25 | $120.4M | $-54.2M | ||
| Q3 25 | $190.0M | $-45.8M | ||
| Q2 25 | $46.7M | $-65.9M | ||
| Q1 25 | $-365.0K | $-67.1M | ||
| Q4 24 | $10.7M | $-83.4M | ||
| Q3 24 | $112.6M | $-55.3M | ||
| Q2 24 | $71.2M | $-99.1M | ||
| Q1 24 | $-120.0M | $-37.2M |
自由现金流率EXASGH
| Q4 25 | 13.7% | -19.3% | ||
| Q3 25 | 22.3% | -17.3% | ||
| Q2 25 | 5.8% | -28.4% | ||
| Q1 25 | -0.1% | -33.0% | ||
| Q4 24 | 1.5% | -41.3% | ||
| Q3 24 | 15.9% | -28.9% | ||
| Q2 24 | 10.2% | -55.9% | ||
| Q1 24 | -18.8% | -22.1% |
资本支出强度EXASGH
| Q4 25 | 3.6% | 9.9% | ||
| Q3 25 | 3.5% | 3.9% | ||
| Q2 25 | 5.2% | 2.4% | ||
| Q1 25 | 4.4% | 2.2% | ||
| Q4 24 | 5.1% | 9.4% | ||
| Q3 24 | 3.7% | 2.2% | ||
| Q2 24 | 5.1% | 2.9% | ||
| Q1 24 | 5.9% | 4.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
